Skip to main content
Top
Published in: CNS Drugs 1/2017

01-01-2017 | Original Research Article

Anesthetics and Outcome in Status Epilepticus: A Matched Two-Center Cohort Study

Authors: Raoul Sutter, Gian Marco De Marchis, Saskia Semmlack, Peter Fuhr, Stephan Rüegg, Stephan Marsch, Wendy C. Ziai, Peter W. Kaplan

Published in: CNS Drugs | Issue 1/2017

Login to get access

Abstract

Background

The use of anesthetics has been linked to poor outcome in patients with status epilepticus (SE). This association, however, may be confounded, as anesthetics are mostly administered in patients with more severe SE and critical illnesses.

Objective

To minimize treatment-selection bias, we assessed the association between continuously administered intravenous anesthetic drugs (IVADs) and outcome in SE patients by a matched two-center study design.

Methods

This cohort study was performed at the Johns Hopkins Bayview Medical Center, Baltimore, MD, USA and the University Hospital Basel, Basel, Switzerland. All consecutive adult SE patients from 2005 to 2013 were included. Odds ratios (ORs) for death and unfavorable outcome (Glasgow Outcome Score [GOS] 1–3) associated with administration of IVADs were calculated. To account for confounding by known outcome determinants (age, level of consciousness, worst seizure type, acute/fatal etiology, mechanical ventilation, and SE duration), propensity score matching and coarsened exact matching were performed in addition to multivariable regression models.

Results

Among 406 consecutive patients, 139 (34.2%) were treated with IVADs. Logistic regression analyses of the unmatched and matched cohorts revealed increased odds for death and unfavorable outcome in survivors who had received IVADs (unmatched: ORdeath = 3.13, 95% confidence interval [CI] 1.47–6.60 and ORGOS1–3 = 2.51, 95% CI 1.37–4.60; propensity score matched: ORdeath = 3.29, 95% CI 1.35–8.05 and ORGOS1–3 = 2.27, 95% CI 1.02–5.06; coarsened exact matched: ORdeath = 2.19, 95% CI 1.27–3.78 and ORGOS1–3 = 3.94, 95% CI 2.12–7.32).

Conclusion

The use of IVADs in SE is associated with death and unfavorable outcome in survivors independent of known confounders and using different statistical approaches. Randomized trials are needed to determine if these associations are biased by outcome predictors not yet identified and hence not accounted for in this study.
Literature
1.
go back to reference Treiman DM, Meyers PD, Walton NY, et al. A comparison of four treatments for generalized convulsive status epilepticus: Veterans Affairs Status Epilepticus Cooperative Study Group. N Engl J Med. 1998;339(12):792–8.CrossRefPubMed Treiman DM, Meyers PD, Walton NY, et al. A comparison of four treatments for generalized convulsive status epilepticus: Veterans Affairs Status Epilepticus Cooperative Study Group. N Engl J Med. 1998;339(12):792–8.CrossRefPubMed
2.
go back to reference Brophy GM, Bell R, Claassen J, et al. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care. 2012;17(1):3–23.CrossRefPubMed Brophy GM, Bell R, Claassen J, et al. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care. 2012;17(1):3–23.CrossRefPubMed
3.
go back to reference Meierkord H, Boon P, Engelsen B, et al. EFNS guideline on the management of status epilepticus in adults. Eur J Neurol. 2010;17(3):348–55.CrossRefPubMed Meierkord H, Boon P, Engelsen B, et al. EFNS guideline on the management of status epilepticus in adults. Eur J Neurol. 2010;17(3):348–55.CrossRefPubMed
4.
go back to reference Sutter R, Marsch S, Fuhr P, Rüegg S. Mortality and recovery from refractory status epilepticus in the ICU: a 7-year observational study. Epilepsia. 2013;54(3):502–11.CrossRefPubMed Sutter R, Marsch S, Fuhr P, Rüegg S. Mortality and recovery from refractory status epilepticus in the ICU: a 7-year observational study. Epilepsia. 2013;54(3):502–11.CrossRefPubMed
5.
go back to reference Holtkamp M, Masuhr F, Harms L, et al. The management of refractory generalised convulsive and complex partial status epilepticus in three European countries: a survey among epileptologists and critical care neurologists. J Neurol Neurosurg Psychiatry. 2003;74(8):1095–9.CrossRefPubMedPubMedCentral Holtkamp M, Masuhr F, Harms L, et al. The management of refractory generalised convulsive and complex partial status epilepticus in three European countries: a survey among epileptologists and critical care neurologists. J Neurol Neurosurg Psychiatry. 2003;74(8):1095–9.CrossRefPubMedPubMedCentral
7.
go back to reference Rossetti AO, Milligan TA, Vulliemoz S, et al. A randomized trial for the treatment of refractory status epilepticus. Neurocrit Care. 2011;14(1):4–10.CrossRefPubMed Rossetti AO, Milligan TA, Vulliemoz S, et al. A randomized trial for the treatment of refractory status epilepticus. Neurocrit Care. 2011;14(1):4–10.CrossRefPubMed
8.
go back to reference Parviainen I, Kalviainen R, Ruokonen E. Propofol and barbiturates for the anesthesia of refractory convulsive status epilepticus: pros and cons. Neurol Res. 2007;29(7):667–71.CrossRefPubMed Parviainen I, Kalviainen R, Ruokonen E. Propofol and barbiturates for the anesthesia of refractory convulsive status epilepticus: pros and cons. Neurol Res. 2007;29(7):667–71.CrossRefPubMed
9.
go back to reference Kowalski RG, Ziai WC, Rees RN, et al. Third-line antiepileptic therapy and outcome in status epilepticus: the impact of vasopressor use and prolonged mechanical ventilation. Crit Care Med. 2012;40(9):2677–84.CrossRefPubMed Kowalski RG, Ziai WC, Rees RN, et al. Third-line antiepileptic therapy and outcome in status epilepticus: the impact of vasopressor use and prolonged mechanical ventilation. Crit Care Med. 2012;40(9):2677–84.CrossRefPubMed
10.
11.
go back to reference Marchi NA, Novy J, Faouzi M, et al. Status epilepticus: impact of therapeutic coma on outcome. Crit Care Med. 2015;43(5):1003–9.CrossRefPubMed Marchi NA, Novy J, Faouzi M, et al. Status epilepticus: impact of therapeutic coma on outcome. Crit Care Med. 2015;43(5):1003–9.CrossRefPubMed
12.
go back to reference von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453–7.CrossRef von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453–7.CrossRef
13.
go back to reference Rossetti AO, Logroscino G, Liaudet L, et al. Status epilepticus: an independent outcome predictor after cerebral anoxia. Neurology. 2007;69(3):255–60.CrossRefPubMed Rossetti AO, Logroscino G, Liaudet L, et al. Status epilepticus: an independent outcome predictor after cerebral anoxia. Neurology. 2007;69(3):255–60.CrossRefPubMed
14.
go back to reference Rossetti AO, Logroscino G, Bromfield EB. A clinical score for prognosis of status epilepticus in adults. Neurology. 2006;66(11):1736–8.CrossRefPubMed Rossetti AO, Logroscino G, Bromfield EB. A clinical score for prognosis of status epilepticus in adults. Neurology. 2006;66(11):1736–8.CrossRefPubMed
15.
go back to reference Rossetti AO, Logroscino G, Milligan TA, et al. Status Epilepticus Severity Score (STESS): a tool to orient early treatment strategy. J Neurol. 2008;255(10):1561–6.CrossRefPubMed Rossetti AO, Logroscino G, Milligan TA, et al. Status Epilepticus Severity Score (STESS): a tool to orient early treatment strategy. J Neurol. 2008;255(10):1561–6.CrossRefPubMed
16.
go back to reference Sutter R, Kaplan PW, Rüegg S. Independent external validation of the Status Epilepticus Severity Score. Crit Care Med. 2013;41:e475–9.CrossRefPubMed Sutter R, Kaplan PW, Rüegg S. Independent external validation of the Status Epilepticus Severity Score. Crit Care Med. 2013;41:e475–9.CrossRefPubMed
17.
go back to reference Sutter R, Tschudin-Sutter S, Grize L, et al. Associations between infections and clinical outcome parameters in status epilepticus: a retrospective 5-year cohort study. Epilepsia. 2012;53(9):1489–97.CrossRefPubMed Sutter R, Tschudin-Sutter S, Grize L, et al. Associations between infections and clinical outcome parameters in status epilepticus: a retrospective 5-year cohort study. Epilepsia. 2012;53(9):1489–97.CrossRefPubMed
18.
go back to reference Kroeger D, Amzica F. Hypersensitivity of the anesthesia-induced comatose brain. J Neurosci. 2007;27(39):10597–607.CrossRefPubMed Kroeger D, Amzica F. Hypersensitivity of the anesthesia-induced comatose brain. J Neurosci. 2007;27(39):10597–607.CrossRefPubMed
19.
go back to reference Lowenstein DH, Bleck T, Macdonald RL. It’s time to revise the definition of status epilepticus. Epilepsia. 1999;40(1):120–2.CrossRefPubMed Lowenstein DH, Bleck T, Macdonald RL. It’s time to revise the definition of status epilepticus. Epilepsia. 1999;40(1):120–2.CrossRefPubMed
20.
go back to reference Sutter R, Kaplan PW, Rüegg S. Outcome predictors for status epilepticus: what really counts. Nat Rev Neurol. 2013;9(9):525–34.CrossRefPubMed Sutter R, Kaplan PW, Rüegg S. Outcome predictors for status epilepticus: what really counts. Nat Rev Neurol. 2013;9(9):525–34.CrossRefPubMed
21.
go back to reference Sutter R, Kaplan PW. Can anesthetic treatment worsen outcome in status epilepticus? Epilepsy Behav. 2015;49:294–7.CrossRefPubMed Sutter R, Kaplan PW. Can anesthetic treatment worsen outcome in status epilepticus? Epilepsy Behav. 2015;49:294–7.CrossRefPubMed
22.
go back to reference Rosenbaum PR, Rubin DB. Contructing a control group using multivariate matched sampling methods that incoroporate the propensity score. Am Stat. 1985;39(1):33–8. Rosenbaum PR, Rubin DB. Contructing a control group using multivariate matched sampling methods that incoroporate the propensity score. Am Stat. 1985;39(1):33–8.
23.
24.
go back to reference King G, Nielsen R, Coberley C, et al. Comparative effectiveness of matching methods for causal inference. 2011. http://j.mp/jCpWmk. Accessed 19 Oct 2016. King G, Nielsen R, Coberley C, et al. Comparative effectiveness of matching methods for causal inference. 2011. http://​j.​mp/​jCpWmk. Accessed 19 Oct 2016.
25.
go back to reference Etsten B, Li TH. Hemodynamic changes during thiopental anesthesia in humans: cardiac output, stroke volume, total peripheral resistance, and intrathoracic blood volume. J Clin Invest. 1955;34(3):500–10.CrossRefPubMedPubMedCentral Etsten B, Li TH. Hemodynamic changes during thiopental anesthesia in humans: cardiac output, stroke volume, total peripheral resistance, and intrathoracic blood volume. J Clin Invest. 1955;34(3):500–10.CrossRefPubMedPubMedCentral
26.
go back to reference Claassen J, Hirsch LJ, Emerson RG, Mayer SA. Treatment of refractory status epilepticus with pentobarbital, propofol, or midazolam: a systematic review. Epilepsia. 2002;43(2):146–53.CrossRefPubMed Claassen J, Hirsch LJ, Emerson RG, Mayer SA. Treatment of refractory status epilepticus with pentobarbital, propofol, or midazolam: a systematic review. Epilepsia. 2002;43(2):146–53.CrossRefPubMed
27.
go back to reference Sperry JL, Minei JP, Frankel HL, et al. Early use of vasopressors after injury: caution before constriction. J Trauma. 2008;64(1):9–14.CrossRefPubMed Sperry JL, Minei JP, Frankel HL, et al. Early use of vasopressors after injury: caution before constriction. J Trauma. 2008;64(1):9–14.CrossRefPubMed
28.
go back to reference Guerin JP, Levraut J, Samat-Long C, et al. Effects of dopamine and norepinephrine on systemic and hepatosplanchnic hemodynamics, oxygen exchange, and energy balance in vasoplegic septic patients. Shock. 2005;23(1):18–24.CrossRefPubMed Guerin JP, Levraut J, Samat-Long C, et al. Effects of dopamine and norepinephrine on systemic and hepatosplanchnic hemodynamics, oxygen exchange, and energy balance in vasoplegic septic patients. Shock. 2005;23(1):18–24.CrossRefPubMed
29.
go back to reference Tsapenko MV, Tsapenko AV, Comfere TB, et al. Arterial pulmonary hypertension in noncardiac intensive care unit. Vasc Health Risk Manag. 2008;4(5):1043–60.CrossRefPubMedPubMedCentral Tsapenko MV, Tsapenko AV, Comfere TB, et al. Arterial pulmonary hypertension in noncardiac intensive care unit. Vasc Health Risk Manag. 2008;4(5):1043–60.CrossRefPubMedPubMedCentral
30.
go back to reference Muzevich KM, Voils SA. Role of vasopressor administration in patients with acute neurologic injury. Neurocrit Care. 2009;11(1):112–9.CrossRefPubMed Muzevich KM, Voils SA. Role of vasopressor administration in patients with acute neurologic injury. Neurocrit Care. 2009;11(1):112–9.CrossRefPubMed
31.
go back to reference Gaspard N, Foreman BP, Alvarez V, et al. New-onset refractory status epilepticus: etiology, clinical features, and outcome. Neurology. 2015;85(18):1604–13.CrossRefPubMedPubMedCentral Gaspard N, Foreman BP, Alvarez V, et al. New-onset refractory status epilepticus: etiology, clinical features, and outcome. Neurology. 2015;85(18):1604–13.CrossRefPubMedPubMedCentral
32.
go back to reference Parviainen I, Uusaro A, Kalviainen R, et al. Propofol in the treatment of refractory status epilepticus. Intensive Care Med. 2006;32(7):1075–9.CrossRefPubMed Parviainen I, Uusaro A, Kalviainen R, et al. Propofol in the treatment of refractory status epilepticus. Intensive Care Med. 2006;32(7):1075–9.CrossRefPubMed
33.
go back to reference Prabhakar H, Bindra A, Singh GP, Kalaivani M. Propofol versus thiopental sodium for the treatment of refractory status epilepticus. Cochrane Database Syst Rev. 2012;15(8):CD009202. Prabhakar H, Bindra A, Singh GP, Kalaivani M. Propofol versus thiopental sodium for the treatment of refractory status epilepticus. Cochrane Database Syst Rev. 2012;15(8):CD009202.
35.
go back to reference Novy J, Logroscino G, Rossetti AO. Refractory status epilepticus: a prospective observational study. Epilepsia. 2010;51(2):251–6.CrossRefPubMed Novy J, Logroscino G, Rossetti AO. Refractory status epilepticus: a prospective observational study. Epilepsia. 2010;51(2):251–6.CrossRefPubMed
36.
go back to reference Agan K, Afsar N, Midi I, et al. Predictors of refractoriness in a Turkish status epilepticus data bank. Epilepsy Behav. 2009;14(4):651–4.CrossRefPubMed Agan K, Afsar N, Midi I, et al. Predictors of refractoriness in a Turkish status epilepticus data bank. Epilepsy Behav. 2009;14(4):651–4.CrossRefPubMed
37.
go back to reference Zelano J, Moller F, Dobesberger J, et al. Infections in status epilepticus: a retrospective 5-year cohort study. Seizure. 2014;23(8):603–6.CrossRefPubMed Zelano J, Moller F, Dobesberger J, et al. Infections in status epilepticus: a retrospective 5-year cohort study. Seizure. 2014;23(8):603–6.CrossRefPubMed
38.
go back to reference Knake S, Rosenow F, Vescovi M, et al. Incidence of status epilepticus in adults in Germany: a prospective, population-based study. Epilepsia. 2001;42(6):714–8.CrossRefPubMed Knake S, Rosenow F, Vescovi M, et al. Incidence of status epilepticus in adults in Germany: a prospective, population-based study. Epilepsia. 2001;42(6):714–8.CrossRefPubMed
39.
go back to reference Trinka E, Cock H, Hesdorffer D, et al. A definition and classification of status epilepticus: report of the ILAE Task Force on Classification of Status Epilepticus. Epilepsia. 2015;56(10):1515–23.CrossRefPubMed Trinka E, Cock H, Hesdorffer D, et al. A definition and classification of status epilepticus: report of the ILAE Task Force on Classification of Status Epilepticus. Epilepsia. 2015;56(10):1515–23.CrossRefPubMed
40.
go back to reference Hocker S, Nagarajan E, Rabinstein AA, et al. Progressive brain atrophy in super-refractory status epilepticus. JAMA Neurol. 2016;73(10):1201–7.CrossRefPubMed Hocker S, Nagarajan E, Rabinstein AA, et al. Progressive brain atrophy in super-refractory status epilepticus. JAMA Neurol. 2016;73(10):1201–7.CrossRefPubMed
41.
go back to reference Sutter R. Conflicting clinical implications of therapeutic coma for status epilepticus. Crit Care Med. 2015;43(5):1144–5.CrossRefPubMed Sutter R. Conflicting clinical implications of therapeutic coma for status epilepticus. Crit Care Med. 2015;43(5):1144–5.CrossRefPubMed
42.
go back to reference Ferguson M, Bianchi MT, Sutter R, et al. Calculating the risk benefit equation for aggressive treatment of non-convulsive status epilepticus. Neurocrit Care. 2012;18(2):216–27.CrossRef Ferguson M, Bianchi MT, Sutter R, et al. Calculating the risk benefit equation for aggressive treatment of non-convulsive status epilepticus. Neurocrit Care. 2012;18(2):216–27.CrossRef
Metadata
Title
Anesthetics and Outcome in Status Epilepticus: A Matched Two-Center Cohort Study
Authors
Raoul Sutter
Gian Marco De Marchis
Saskia Semmlack
Peter Fuhr
Stephan Rüegg
Stephan Marsch
Wendy C. Ziai
Peter W. Kaplan
Publication date
01-01-2017
Publisher
Springer International Publishing
Published in
CNS Drugs / Issue 1/2017
Print ISSN: 1172-7047
Electronic ISSN: 1179-1934
DOI
https://doi.org/10.1007/s40263-016-0389-5

Other articles of this Issue 1/2017

CNS Drugs 1/2017 Go to the issue